COHU INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that COHU INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $84.09M | Mar 2, 2018 |
| FY2017 | Sep 30, 2017 | $93.65M | Mar 2, 2018 |
| FY2017 | Jul 1, 2017 | $93.87M | Mar 2, 2018 |
| FY2017 | Apr 1, 2017 | $81.10M | Mar 2, 2018 |
| FY2017 | Dec 31, 2016 | $70.69M | Mar 2, 2018 |
| FY2017 | Sep 24, 2016 | $69.26M | Mar 2, 2018 |
| FY2017 | Jun 25, 2016 | $76.35M | Mar 2, 2018 |
| FY2017 | Mar 26, 2016 | $65.78M | Mar 2, 2018 |
| FY2016 | Dec 26, 2015 | $63.48M | Mar 2, 2017 |
| FY2016 | Sep 26, 2015 | $67.51M | Mar 2, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $34.42M | Mar 2, 2018 |
| FY2017 | Sep 30, 2017 | $36.91M | Mar 2, 2018 |
| FY2017 | Jul 1, 2017 | $37.13M | Mar 2, 2018 |
| FY2017 | Apr 1, 2017 | $32.26M | Mar 2, 2018 |
| FY2016 | Dec 31, 2016 | $25.53M | Mar 2, 2017 |
| FY2016 | Sep 24, 2016 | $23.28M | Mar 2, 2017 |
| FY2016 | Jun 25, 2016 | $26.74M | Mar 2, 2017 |
| FY2016 | Mar 26, 2016 | $19.28M | Mar 2, 2017 |
| FY2015 | Dec 26, 2015 | $20.40M | Feb 23, 2016 |
| FY2015 | Sep 26, 2015 | $22.79M | Feb 23, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($74.27M) | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | ($69.82M) | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | $28.16M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $96.85M | Feb 20, 2025 |
| FY2023 | Dec 25, 2021 | $167.33M | Feb 16, 2024 |
| FY2020 | Dec 26, 2020 | $14.86M | Feb 26, 2021 |
| FY2020 | Sep 26, 2020 | ($6.65M) | Feb 26, 2021 |
| FY2020 | Jun 27, 2020 | ($4.74M) | Feb 26, 2021 |
| FY2020 | Mar 28, 2020 | ($17.28M) | Feb 26, 2021 |
| FY2020 | Dec 28, 2019 | ($17.27M) | Feb 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | ($69.77M) | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | ($71.67M) | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | $43.27M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $125.56M | Feb 20, 2025 |
| FY2023 | Dec 25, 2021 | $201.52M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $3.26M | Feb 17, 2023 |
| FY2021 | Dec 28, 2019 | ($52.33M) | Feb 18, 2022 |
| FY2020 | Dec 29, 2018 | ($29.78M) | Feb 26, 2021 |
| FY2019 | Dec 30, 2017 | $37.73M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $3.04M | Mar 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $92.21M | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | $84.80M | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | $88.57M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $92.59M | Feb 20, 2025 |
| FY2023 | Dec 25, 2021 | $91.96M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $86.15M | Feb 17, 2023 |
| FY2021 | Dec 28, 2019 | $86.15M | Feb 18, 2022 |
| FY2020 | Dec 29, 2018 | $56.43M | Feb 26, 2021 |
| FY2019 | Dec 30, 2017 | $40.74M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $34.84M | Mar 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $123.57M | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | $128.04M | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | $132.25M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $131.39M | Feb 20, 2025 |
| FY2023 | Dec 25, 2021 | $126.96M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $129.25M | Feb 17, 2023 |
| FY2021 | Dec 28, 2019 | $142.94M | Feb 18, 2022 |
| FY2020 | Dec 29, 2018 | $96.75M | Feb 26, 2021 |
| FY2019 | Dec 30, 2017 | $60.74M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $55.21M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $31.69M | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | $2.78M | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | $101.47M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $112.86M | Feb 20, 2025 |
| FY2023 | Dec 25, 2021 | $97.92M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $49.88M | Feb 17, 2023 |
| FY2021 | Dec 28, 2019 | $17.27M | Feb 18, 2022 |
| FY2020 | Dec 29, 2018 | $34.44M | Feb 26, 2021 |
| FY2019 | Dec 30, 2017 | $39.75M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $24.55M | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $20.96M | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | $10.63M | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | $16.05M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $14.77M | Feb 20, 2025 |
| FY2023 | Dec 25, 2021 | $12.00M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $18.66M | Feb 17, 2023 |
| FY2021 | Dec 28, 2019 | $18.00M | Feb 18, 2022 |
| FY2020 | Dec 29, 2018 | $4.97M | Feb 26, 2021 |
| FY2019 | Dec 30, 2017 | $6.09M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $3.45M | Mar 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $1.24B | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | $999.42M | Feb 17, 2026 |
| FY2024 | Dec 30, 2023 | $1.15B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.23B | Feb 16, 2024 |
| FY2022 | Dec 25, 2021 | $1.26B | Feb 17, 2023 |
| FY2022 | Dec 26, 2020 | $1.09B | Feb 17, 2023 |
| FY2021 | Dec 28, 2019 | $1.08B | Feb 18, 2022 |
| FY2020 | Dec 29, 2018 | $1.13B | Feb 26, 2021 |
| FY2019 | Dec 30, 2017 | $420.46M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $345.51M | Mar 14, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $785.54M | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | $856.89M | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | $950.17M | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | $928.84M | Feb 17, 2026 |
| FY2024 | Dec 25, 2021 | $882.50M | Feb 20, 2025 |
| FY2023 | Dec 26, 2020 | $512.29M | Feb 16, 2024 |
| FY2022 | Dec 28, 2019 | $483.07M | Feb 17, 2023 |
| FY2019 | Dec 29, 2018 | $546.24M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $289.09M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $235.47M | Mar 2, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $283.03M | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | $234.64M | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | $241.66M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $213.54M | Feb 20, 2025 |
| FY2023 | Dec 25, 2021 | $219.79M | Feb 16, 2024 |
| FY2022 | Dec 26, 2020 | $252.30M | Feb 17, 2023 |
| FY2021 | Dec 28, 2019 | $238.67M | Feb 18, 2022 |
| FY2020 | Dec 29, 2018 | $242.13M | Feb 26, 2021 |
| FY2019 | Dec 30, 2017 | $65.61M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $58.85M | Mar 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $174.47M | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | $248.74M | Feb 17, 2026 |
| FY2024 | Dec 30, 2023 | $318.56M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $290.40M | Feb 16, 2024 |
| FY2022 | Dec 25, 2021 | $193.56M | Feb 17, 2023 |
| FY2021 | Dec 26, 2020 | $26.23M | Feb 18, 2022 |
| FY2020 | Dec 28, 2019 | $42.52M | Feb 26, 2021 |
| FY2019 | Dec 29, 2018 | $111.67M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $151.78M | Mar 14, 2019 |
| FY2018 | Dec 30, 2017 | $150.73M | Mar 14, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $227.05M | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | $206.41M | Feb 17, 2026 |
| FY2024 | Dec 30, 2023 | $245.52M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $242.34M | Feb 16, 2024 |
| FY2022 | Dec 25, 2021 | $290.20M | Feb 17, 2023 |
| FY2021 | Dec 26, 2020 | $149.36M | Feb 18, 2022 |
| FY2021 | Dec 28, 2019 | $155.19M | Feb 18, 2022 |
| FY2020 | Dec 29, 2018 | $164.46M | Feb 26, 2021 |
| FY2019 | Dec 30, 2017 | $134.29M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $96.05M | Mar 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $305.09M | Feb 17, 2026 |
| FY2024 | Dec 28, 2024 | $8.80M | Feb 20, 2025 |
| FY2023 | Dec 30, 2023 | $40.88M | Feb 16, 2024 |
| FY2022 | Dec 31, 2022 | $79.74M | Feb 17, 2023 |
| FY2021 | Dec 25, 2021 | $119.30M | Feb 18, 2022 |
| FY2020 | Dec 26, 2020 | $325.51M | Feb 26, 2021 |
| FY2019 | Dec 28, 2019 | $360.48M | Mar 10, 2020 |
| FY2018 | Dec 29, 2018 | $358.66M | Mar 14, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | (1) | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | (1) | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | 0 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 20, 2025 |
| FY2023 | Dec 25, 2021 | 3 | Feb 16, 2024 |
| FY2020 | Dec 26, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 26, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 28, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 28, 2019 | 0 | Feb 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | (1) | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | (1) | Feb 17, 2026 |
| FY2025 | Dec 30, 2023 | 0 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 20, 2025 |
| FY2023 | Dec 25, 2021 | 3 | Feb 16, 2024 |
| FY2020 | Dec 26, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 26, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 28, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 28, 2019 | 0 | Feb 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | 49.88M | Feb 17, 2026 |
| FY2025 | Dec 28, 2024 | 49.60M | Feb 17, 2026 |
| FY2024 | Dec 30, 2023 | 49.43M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 49.28M | Feb 16, 2024 |
| FY2022 | Dec 25, 2021 | 48.76M | Feb 17, 2023 |
| FY2021 | Dec 26, 2020 | 42.19M | Feb 18, 2022 |
| FY2020 | Dec 28, 2019 | 41.40M | Feb 26, 2021 |
| FY2019 | Dec 29, 2018 | 40.76M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | 28.49M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 26.84M | Mar 2, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Feb 17, 2023 |
| FY2022 | Dec 25, 2021 | $0 | Feb 17, 2023 |
| FY2022 | Dec 26, 2020 | $4.97M | Feb 17, 2023 |
| FY2021 | Dec 28, 2019 | $9.83M | Feb 18, 2022 |
| FY2020 | Dec 29, 2018 | $6.95M | Feb 26, 2021 |
| FY2019 | Dec 30, 2017 | $6.58M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $6.35M | Mar 14, 2019 |
| FY2017 | Dec 26, 2015 | $6.22M | Mar 2, 2018 |
| FY2016 | Dec 27, 2014 | $6.07M | Mar 2, 2017 |
| FY2015 | Dec 28, 2013 | $4.47M | Feb 23, 2016 |